Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919128 | 0.90 | MAPT (0.48) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL2895010 | 0.90 | PTPN1 (0.51) | BCHECNR2IDO1PTPN1PTPN22 | |
| SCHEMBL7778567 | 0.87 | KDM4E (0.55) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL3918481 | 0.86 | IDO1 (0.48) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL8821227 | 0.85 | SCN9A (0.51) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL3915966 | 0.85 | CA12 (0.49) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL3926178 | 0.85 | IDO1 (0.47) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL3927385 | 0.84 | PTPN1 (0.54) | PTPN1PTPN22 | |
| SCHEMBL3919830 | 0.84 | CA12 (0.46) | BCHECNR2IDO1CA12CA1 | |
| SCHEMBL1978348 | 0.83 | DRD2 (0.51) | CA12CA1CA2CA9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | BCHE 1781/4885CNR2 3196/4885IDO1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.